The estimated Net Worth of Perkins Caufield & Byers Xi... is at least $190 Million dollars as of 5 August 2019. Perkins Xi owns over 723,862 units of Oyster Point Pharma Inc stock worth over $78,498,303 and over the last 6 years Perkins sold OYST stock worth over $111,474,748.
Perkins has made over 1 trades of the Oyster Point Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Perkins sold 723,862 units of OYST stock worth $111,474,748 on 5 August 2019.
The largest trade Perkins's ever made was selling 723,862 units of Oyster Point Pharma Inc stock on 5 August 2019 worth over $111,474,748. On average, Perkins trades about 180,966 units every 0 days since 2019. As of 5 August 2019 Perkins still owns at least 7,027,601 units of Oyster Point Pharma Inc stock.
You can see the complete history of Perkins Xi stock trades at the bottom of the page.
Over the last 5 years, insiders at Oyster Point Pharma Inc have traded over $24,486,000 worth of Oyster Point Pharma Inc stock and bought 3,552,871 units worth $59,028,668 . The most active insiders traders include Ali Behbahani, Venture Capital Vi, L.P.Ver..., and Clare Ozawa. On average, Oyster Point Pharma Inc executives and independent directors trade stock every 27 days with the average trade being worth of $2,204,444. The most recent stock trade was executed by Daniel Lochner on 1 November 2021, trading 8,590 units of OYST stock currently worth $98,871.
Oyster Point Pharma is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ocular surface diseases. Oyster Point Pharma's lead product candidate, OC-01 (varenicline) nasal spray, a highly selective cholinergic agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease. In pre-clinical and clinical studies, OC-01 (varenicline) nasal spray was shown to have a novel mechanism of action via activation of the trigeminal parasympathetic pathway to stimulate the glands and cells responsible for natural tear film production, known as the lacrimal functional unit.
Oyster Point Pharma Inc executives and other stock owners filed with the SEC include: